SFDA To Strengthen Electronic Monitoring Of Drugs
This article was originally published in PharmAsia News
Executive Summary
By building a national surveillance network on the special drug monitoring platform launched last October, China State FDA will further strengthen electronic drug monitoring by gradually phasing in an electronic identification system. Anesthetics and category 1 psychotropic drugs are already under surveillance, while key pharmaceutical production and circulation companies will be mandated to electronically tag category 2 psychotropic drugs, plasma products, vaccines and TCM injections by Oct. 31. SFDA will draw up a catalog that includes all approved registered drugs to be entered in the surveillance network; firms involved must stick standard electronic codes on their smallest product packs before marketing. Once the electronic network is established, consumers may check on drugs by calling or go online via mobile phones. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.